X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (7452) 7452
Book Chapter (23) 23
Publication (10) 10
Dissertation (7) 7
Newspaper Article (5) 5
Book / eBook (2) 2
Conference Proceeding (1) 1
Government Document (1) 1
Magazine Article (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
immunotherapy (3868) 3868
humans (3348) 3348
oncology (3211) 3211
pd-1 (2883) 2883
cancer (2669) 2669
immunology (2169) 2169
pd-1 blockade (1993) 1993
pd-1 protein (1925) 1925
tumors (1883) 1883
lymphocytes (1877) 1877
melanoma (1616) 1616
animals (1533) 1533
lymphocytes t (1529) 1529
nivolumab (1468) 1468
immune checkpoint (1459) 1459
female (1421) 1421
expression (1415) 1415
apoptosis (1381) 1381
t cells (1228) 1228
pd-l1 (1146) 1146
male (1144) 1144
blockade (1117) 1117
pd-l1 protein (1114) 1114
patients (1072) 1072
chemotherapy (1045) 1045
pembrolizumab (1034) 1034
antigens (954) 954
mice (951) 951
care and treatment (940) 940
ipilimumab (923) 923
metastasis (921) 921
middle aged (884) 884
ligands (875) 875
cancer therapies (859) 859
t-cells (857) 857
immune system (771) 771
aged (759) 759
programmed cell death 1 receptor - antagonists & inhibitors (759) 759
therapy (753) 753
research (752) 752
lung cancer (749) 749
cell death (738) 738
safety (730) 730
cytotoxicity (729) 729
survival (716) 716
adult (693) 693
biomarkers (693) 693
immune response (689) 689
clinical trials (681) 681
metastases (666) 666
open-label (659) 659
programmed cell death 1 receptor - immunology (643) 643
cd8 antigen (642) 642
mutation (633) 633
ctla-4 (631) 631
immunotherapy - methods (622) 622
health aspects (615) 615
gene expression (613) 613
dendritic cells (612) 612
medicine, research & experimental (596) 596
review (595) 595
cell biology (592) 592
neoplasms - immunology (585) 585
prognosis (583) 583
analysis (576) 576
programmed cell death 1 receptor - metabolism (561) 561
antibodies (548) 548
activation (546) 546
cytokines (529) 529
anti-pd-1 (528) 528
cd8-positive t-lymphocytes - immunology (521) 521
medical prognosis (519) 519
antibodies, monoclonal - therapeutic use (514) 514
immunity (514) 514
tumor-infiltrating lymphocytes (513) 513
t-lymphocytes - immunology (504) 504
proteins (498) 498
metastatic melanoma (494) 494
responses (492) 492
t cell receptors (479) 479
tumor microenvironment (478) 478
multidisciplinary sciences (477) 477
medical research (464) 464
ctla-4 blockade (459) 459
b7-h1 antigen - metabolism (454) 454
cell lung-cancer (443) 443
flow cytometry (438) 438
ctla-4 protein (437) 437
immunohistochemistry (435) 435
medicine & public health (430) 430
treatment outcome (430) 430
antibody (427) 427
regulatory t-cells (419) 419
mice, inbred c57bl (410) 410
cell line, tumor (409) 409
neoplasms - therapy (409) 409
hematology (406) 406
b7-h1 antigen - antagonists & inhibitors (390) 390
b7-h1 antigen - immunology (387) 387
immunoglobulins (387) 387
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (7400) 7400
German (45) 45
French (41) 41
Japanese (12) 12
Korean (7) 7
Chinese (4) 4
Spanish (3) 3
Russian (2) 2
Hungarian (1) 1
Polish (1) 1
Portuguese (1) 1
Turkish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Immunity (Cambridge, Mass.), ISSN 1074-7613, 2019, Volume 50, Issue 1, pp. 181 - 194.e6
An improved understanding of the anti-tumor CD8+ T cell response after checkpoint blockade would enable more informed and effective therapeutic strategies... 
checkpoint blockade | memory | immunotherapy | single-cell | exhaustion | CD8+ T cell | cancer | PD-1 | dysfunction | Tim-3 | CD8 | T cell | METASTATIC MELANOMA | RESPONSES | DIFFERENTIAL EXPRESSION | BIOCONDUCTOR PACKAGE | THERAPY | SET ENRICHMENT ANALYSIS | IMMUNOLOGY | TIM-3 | EXHAUSTION | PD-1 EXPRESSION | T-Lymphocyte Subsets - immunology | Cell Proliferation | Hepatocyte Nuclear Factor 1-alpha - genetics | Antigens, Neoplasm - immunology | Humans | Mice, Inbred C57BL | Neoplasms, Experimental - therapy | Transcriptome | Antibodies, Monoclonal - therapeutic use | Programmed Cell Death 1 Receptor - antagonists & inhibitors | Lymphocytes, Tumor-Infiltrating - drug effects | Hepatocyte Nuclear Factor 1-alpha - metabolism | Hepatitis A Virus Cellular Receptor 2 - antagonists & inhibitors | Animals | Melanoma, Experimental | CD8-Positive T-Lymphocytes - drug effects | Immunotherapy | Neoplasms, Experimental - immunology | Mice | CD8-Positive T-Lymphocytes - immunology | Immunologic Memory - genetics | Lymphocytes, Tumor-Infiltrating - immunology | Memory cells | Immunoglobulins | Immunological memory | Transcription factors | Tumor-infiltrating lymphocytes | Transcription | PD-1 protein | CD8 antigen | Effector cells | Principal components analysis | Lymphocytes T | Gene expression | Ribonucleic acid--RNA | Immune checkpoint | Lymphocytes | Precursors | Population | Software | Cancer | Tumors | CD8+ T cell
Journal Article
Science (American Association for the Advancement of Science), ISSN 1095-9203, 2018, Volume 359, Issue 6382, pp. 1350 - 1355
Journal Article
The New England journal of medicine, ISSN 1533-4406, 2016, Volume 375, Issue 18, pp. 1749 - 1755
Journal Article
Science (American Association for the Advancement of Science), ISSN 1095-9203, 2018, Volume 362, Issue 6411, pp. eaar3593 - 197
Programmed cell death protein–1 (PD-1) and programmed cell death ligand–1 (PD-L1) checkpoint blockade immunotherapy elicits durable antitumor effects in multiple cancers, yet not all patients respond... 
CELL LUNG-CANCER | MISMATCH-REPAIR DEFICIENCY | MUTATIONAL PROCESSES | METASTATIC MELANOMA | CTLA-4 BLOCKADE | MULTIDISCIPLINARY SCIENCES | COPY NUMBER | PROGRAMMED DEATH LIGAND-1 | SEQUENCING DATA | CLINICAL-RESPONSE | SOMATIC MUTATIONS | Antibodies, Monoclonal, Humanized - therapeutic use | Humans | Transcriptome | Programmed Cell Death 1 Receptor - antagonists & inhibitors | Genetic Markers | Cell Cycle Checkpoints | Neoplasms - therapy | Neoplasms - genetics | Antineoplastic Agents, Immunological - therapeutic use | Immunotherapy | Inflammation - genetics | T-Lymphocytes - immunology | Tumor Burden - genetics | Biomarkers, Tumor - genetics | Mutation | Molecular Targeted Therapy - methods | Monoclonal antibodies | Genetic aspects | T cells | Biological markers | Gene expression | Cancer | Tumors | Apoptosis | Cell receptors | Physiological aspects | Diagnosis | Identification and classification | Methods | PD-1 protein | Genomics | Clinical trials | Genomes | Biology | Lymphocytes T | Microsatellite instability | Data bases | Subgroups | Anticancer properties | Proteins | Cell activation | Pembrolizumab | Databases | Antigenicity | Lymphocytes | Deoxyribonucleic acid--DNA | Medical research | Stability | Microsatellites | Mortality | Melanoma | Data processing | Inflammation | Patients | Immune checkpoint | Cell death | Correlation analysis | PD-L1 protein | Biomarkers | Ligands | Antitumor activity | Cutoffs | Solid tumors
Journal Article
The Journal of clinical investigation, ISSN 1558-8238, 2017, Volume 127, Issue 8, pp. 2930 - 2940
Programmed death-1-directed (PD-1-directed) immune checkpoint blockade results in durable antitumor activity in many advanced malignancies... 
CELL LUNG-CANCER | MEDICINE, RESEARCH & EXPERIMENTAL | MELANOMA | PEMBROLIZUMAB | LIGANDS | IMMUNOTHERAPY | SAFETY | TOLERANCE | ADAPTIVE IMMUNE RESISTANCE | EXPRESSION | Immunohistochemistry | Lung Neoplasms - drug therapy | Skin Neoplasms - drug therapy | Humans | Gene Expression Regulation, Neoplastic | Tumor Microenvironment | Programmed Cell Death 1 Receptor - antagonists & inhibitors | Antineoplastic Agents - therapeutic use | Gene Expression Profiling | Interferon-gamma - metabolism | Immune System | Carcinoma - drug therapy | Antibodies, Monoclonal, Humanized - therapeutic use | Signal Transduction | Skin Neoplasms - immunology | Carcinoma - immunology | Programmed Cell Death 1 Receptor - metabolism | Treatment Outcome | Stomach Neoplasms - drug therapy | Stomach Neoplasms - immunology | Carcinoma, Non-Small-Cell Lung - immunology | B7-H1 Antigen - metabolism | Lung Neoplasms - immunology | Pilot Projects | Sequence Analysis, RNA | Biopsy | Melanoma - immunology | Melanoma - drug therapy | ROC Curve | Carcinoma, Non-Small-Cell Lung - drug therapy | PD-1 protein | Lung cancer | Clinical trials | Cytotoxicity | Biology | Lymphocytes T | Cancer therapies | Metastases | Lymphocytes | Adaptation | Antigen presentation | Squamous cell carcinoma | Cytokines | Melanoma | Inflammation | Gene expression | Immune checkpoint | PD-L1 protein | Head and neck cancer | Antitumor activity | Ligands | Interferon | Chemokines | Apoptosis | Tumors
Journal Article
The New England journal of medicine, ISSN 1533-4406, 2018, Volume 378, Issue 21, pp. 1976 - 1986
The study aims to evaluate the efficacy of neoadjuvant programmed death 1 (PD-1) blockade as a form of treatment for patients with resectable advanced non-small-cell lung cancer (NSCLC... 
MISMATCH-REPAIR DEFICIENCY | TRIAL | MEDICINE, GENERAL & INTERNAL | MULTICENTER | PEMBROLIZUMAB | RESPONSE CRITERIA | SOLID TUMORS | IMMUNE CHECKPOINT BLOCKADE | IMMUNOTHERAPY | OPEN-LABEL | CHEMOTHERAPY | Lung Neoplasms - drug therapy | Adenocarcinoma - pathology | Carcinoma, Squamous Cell - pathology | Humans | Middle Aged | Antibodies, Monoclonal - adverse effects | Antibodies, Monoclonal - therapeutic use | Lung Neoplasms - pathology | Male | Antineoplastic Agents - therapeutic use | Antineoplastic Agents - adverse effects | Aged, 80 and over | Female | Neoadjuvant Therapy | Carcinoma, Non-Small-Cell Lung - pathology | Lung Neoplasms - genetics | Carcinoma, Non-Small-Cell Lung - surgery | Carcinoma, Non-Small-Cell Lung - genetics | Pilot Projects | B7-H1 Antigen - antagonists & inhibitors | Biopsy | Nivolumab | Lung Neoplasms - surgery | Aged | Carcinoma, Non-Small-Cell Lung - drug therapy | Mutation | Drug therapy | Lung cancer | Peptides | PD-1 protein | Body weight | Lymphocytes T | Cancer therapies | Lymphocytes | Immunotherapy | Surgery | Peripheral blood | Drug dosages | Antigens | Lymphatic system | Cell survival | Cloning | Feasibility studies | Non-small cell lung carcinoma | T cell receptors | Gene expression | Patients | Side effects | Chemotherapy | PD-L1 protein | Tumors | Apoptosis
Journal Article
Nature (London), ISSN 1476-4687, 2018, Volume 554, Issue 7693, pp. 544 - 548
Therapeutic antibodies that block the programmed death-1 (PD-1)-programmed death-ligand 1 (PD-L1) pathway can induce robust and durable responses in patients... 
METASTATIC MELANOMA | CTLA-4 BLOCKADE | BLADDER-CANCER | THERAPY | LANDSCAPE | SUBTYPES | UROTHELIAL CARCINOMA | MULTIDISCIPLINARY SCIENCES | GENES | ADAPTIVE IMMUNE RESISTANCE | MPDL3280A | CD8-Positive T-Lymphocytes - cytology | Humans | Antibodies, Monoclonal - therapeutic use | Urothelium - pathology | Antibodies, Monoclonal, Humanized | Urologic Neoplasms - pathology | Neoplasm Metastasis | Urologic Neoplasms - drug therapy | Urologic Neoplasms - genetics | Immunotherapy | Antibodies - immunology | Antigens, Neoplasm - metabolism | Transforming Growth Factor beta - antagonists & inhibitors | Antigens, Neoplasm - analysis | Disease Models, Animal | Fibroblasts - metabolism | Antibodies - therapeutic use | Antigens, Neoplasm - immunology | Antibodies, Monoclonal - pharmacology | Treatment Outcome | B7-H1 Antigen - immunology | Urologic Neoplasms - immunology | Antibodies - pharmacology | Tumor Microenvironment - immunology | Collagen - metabolism | Phenotype | Animals | B7-H1 Antigen - antagonists & inhibitors | Signal Transduction - drug effects | Cell Cycle Checkpoints - drug effects | CD8-Positive T-Lymphocytes - drug effects | Urothelium - immunology | Mice | Mutation | CD8-Positive T-Lymphocytes - immunology | Urothelium - drug effects | Transforming Growth Factor beta - metabolism | Cohort Studies | Drug Resistance, Neoplasm - drug effects | PD-1 protein | CD8 antigen | Transforming growth factor-a | Antibodies | Parenchyma | Lymphocytes T | Metastasis | Immunity | Metastases | Genotype & phenotype | Signal transduction | Lymphocytes | Cell cycle | Fibroblasts | Growth factors | Urothelial cancer | Phenotypes | Cytokines | Melanoma | Blocking | Gene expression | Patients | Generalized linear models | Signaling | Stromal cells | Medical prognosis | Collagen | PD-L1 protein | Ligands | Determinants | Infiltration | Cancer | Tumors | Apoptosis | Clinical Medicine | Medical and Health Sciences | Klinisk medicin | Cancer and Oncology | Medicin och hälsovetenskap | Cancer och onkologi
Journal Article
Proceedings of the National Academy of Sciences - PNAS, ISSN 1091-6490, 2019, Volume 116, Issue 20, pp. 9999 - 10008
Journal Article
Science (American Association for the Advancement of Science), ISSN 1095-9203, 2017, Volume 357, Issue 6349, pp. 409 - 413
.... In a proof-of-concept study, we previously showed that colorectal cancers with mismatch repair deficiency were sensitive to immune checkpoint blockade with antibodies to programmed death receptor-1 (PD-1... 
CELL LUNG-CANCER | SURVIVAL | COLORECTAL CARCINOMAS | RECEIVING NIVOLUMAB | IMMUNOTHERAPY | MICROSATELLITE INSTABILITY | MULTIDISCIPLINARY SCIENCES | LONG-TERM SAFETY | NEOANTIGENS | CHECKPOINT BLOCKADE | LYMPHOCYTES | Neoplastic Syndromes, Hereditary - immunology | Colorectal Neoplasms - genetics | Humans | Middle Aged | Male | Programmed Cell Death 1 Receptor - antagonists & inhibitors | Neoplastic Syndromes, Hereditary - mortality | Young Adult | Colorectal Neoplasms - therapy | Brain Neoplasms - immunology | DNA Mismatch Repair | Aged, 80 and over | Adult | Female | Neoplastic Syndromes, Hereditary - genetics | Brain Neoplasms - mortality | Biomarkers, Tumor - antagonists & inhibitors | Colorectal Neoplasms - mortality | Antibodies, Monoclonal, Humanized - therapeutic use | Antigens, Neoplasm - immunology | Brain Neoplasms - genetics | Disease-Free Survival | Colorectal Neoplasms - immunology | Cell Cycle Checkpoints - drug effects | Brain Neoplasms - therapy | Neoplastic Syndromes, Hereditary - therapy | T-Lymphocytes - immunology | Aged | Mutation | Programmed Cell Death 1 Receptor - immunology | Colorectal cancer | Genetic aspects | Nucleotide sequencing | Health aspects | DNA repair | Methods | Tumors | DNA sequencing | Yeast | PD-1 protein | Antibodies | Clinical trials | Genomes | Functional analysis | Lymphocytes T | Patients | Survival | Colon cancer | Immune checkpoint | Immunotherapy | Mismatch repair | Pancreatic cancer | Biomarkers | Colon | Solid tumors | Genetic recombination | Repair | Cancer | Apoptosis
Journal Article
Journal of allergy and clinical immunology, ISSN 0091-6749, 2018, Volume 142, Issue 5, pp. 1403 - 1414
Journal Article